Here is the design of a clinical trial:

Official Title: Is Iron Supplementation Harmful in Populations Where Iron Deficiency is Not the Cause of Anemia? A 12 Week Randomized Controlled Trial in Cambodia

Included conditions:
- Anemia, Iron Deficiency
- Anemia
- Intestinal Inflammation
- Inflammation
- Intestine; Complaints

Study Armgroups:
- {'label': 'Ferrous Sulfate', 'type': 'ACTIVE_COMPARATOR', 'description': 'Iron will be given orally in the form of tablets. A supplement of 60 mg will be taken daily for 12 weeks. World Health Organization standard dose and commonly used form of iron.', 'interventionNames': ['Dietary Supplement: Ferrous sulfate']}
- {'label': 'Ferrous Bisglycinate', 'type': 'EXPERIMENTAL', 'description': 'Iron will be given orally in the form of tablets. A supplement of 18 mg will be taken daily for 12 weeks. Ferrous bisglycinate has a bioavailability 2-4x greater than ferrous sulfate.', 'interventionNames': ['Dietary Supplement: Ferrous Bisglycinate']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Placebo will be given orally in the form of tablets as a control made of microcrystalline cellulose.', 'interventionNames': ['Dietary Supplement: Placebo of microcrystalline cellulose']}

Interventions:
- {'type': 'DIETARY_SUPPLEMENT', 'name': 'Ferrous sulfate', 'description': '60 mg elemental iron as ferrous sulfate', 'armGroupLabels': ['Ferrous Sulfate'], 'otherNames': ['iron sulfate', 'ferrous sulphate', 'iron sulphate', 'Iron(II) sulfate']}
- {'type': 'DIETARY_SUPPLEMENT', 'name': 'Ferrous Bisglycinate', 'description': '18 mg elemental iron as ferrous bisglycinate', 'armGroupLabels': ['Ferrous Bisglycinate'], 'otherNames': ['iron amino acid chelate', 'Iron glycinate', 'Bisglycine iron(II) salt', 'Iron(II) bisglycinate', 'Ferrous Bis-glycinate']}
- {'type': 'DIETARY_SUPPLEMENT', 'name': 'Placebo of microcrystalline cellulose', 'description': 'placebo', 'armGroupLabels': ['Placebo'], 'otherNames': ['Control']}

Primary Outcomes:
- {'measure': 'Serum Ferritin', 'description': 'Serum ferritin concentration (µg/l) at 12 weeks', 'timeFrame': '12 weeks'}
- {'measure': 'Fecal calprotectin', 'description': 'Fecal calprotectin concentration (mg/kg stool) at 12 weeks as a measure of gut inflammation.', 'timeFrame': '12 weeks'}

Please estimate the sample size based on the assumption: 
80% power, α=0.05, SD of ferritin 50 µg/L, 15% loss to follow-up.
Sample size
        We based our calculation on a non-inferiority comparison between the two iron groups. To detect a non-inferiority margin of 20âÂµg/L for ferritin, with 80% power and Î±=0.05, we would require n=140 in each group. WHO has reported a clinically important change in ferritin in response to an iron intervention to be Â±0.2âSD units.56 Data from our 2015 trial indicated the SD of ferritin to be 50âÂµg/L after 12 weeks of 60âmg iron;34 therefore, a margin of 20âÂµg/L was chosen. Thus, we require n=140 in each of the three groups. Accounting for 15% loss to follow-up (a conservative estimate based on our previous trial),34 we require n=160 women in each of the three groups and a total of n=480 women in the study (figure 2).
        
          Figure 2
          
            Participation flowchart.